2 January 2019 - NHS England has announced that from April this year it will fund Novartis' Afinitor (everolimus) for patients living with tuberous sclerosis complex related refractory epilepsy.

Tuberous sclerosis complex (TSC) is a rare genetic condition affecting 1 in 6,000 people that can lead to growths in various organs of the body, with the most common neurological feature being epilepsy, affecting at least eight out of ten people living with the condition.

The development is fantastic news as more than half of people with TSC who have epilepsy do not respond to standard anti-epilepsy medicines, and are in need of an alternative form of treatment - such as Afinitor.

Read Pharma Times article